Elekta AB stock (SE0000163628): radiation therapy specialist in focus after recent earnings and guidance update

Elekta AB, the Swedish specialist for radiation therapy and radiosurgery solutions, has moved back into focus with investors after publishing its nine?month results for the fiscal year 2025/26 and updating its guidance for the full year, according to a company report dated 03/13/2026 from Elekta investor relations as of 03/13/2026.

Beyond the earnings release, the company highlighted continued order intake in key regions and reiterated its strategic focus on software?driven oncology solutions, which keeps the stock on the radar of global healthcare and med?tech portfolios, as reported by Reuters as of 03/13/2026.

As of: 21.05.2026

By the editorial team – specialized in equity coverage.

Elekta AB: core business model

Elekta AB develops, manufactures and services equipment and software for radiation?based cancer treatment and radiosurgery. The company focuses on linear accelerators, brachytherapy systems and planning software that help oncologists deliver precise doses of radiation to tumors while sparing healthy tissue, according to Elekta company information as of 02/2026.

The business is built around long?term relationships with hospitals and cancer centers, where an initial system sale is often followed by years of service contracts, software upgrades and accessories. This installed base strategy provides recurring revenue and visibility, particularly important in a capital?intensive med?tech niche like radiation oncology, as highlighted by Elekta in brief as of 01/2026.

In addition to hardware, Elekta positions itself increasingly as a software and data company. Its oncology information systems and treatment planning platforms integrate imaging, patient records and treatment workflows, which can strengthen customer lock?in and create cross?selling opportunities. This digital angle also helps the group address demand from US healthcare providers for interoperable, data?driven solutions.

Main revenue and product drivers for Elekta AB

According to the nine?month report for the fiscal year 2025/26, Elekta AB continued to generate most of its revenue from sales and service of linear accelerators and related oncology systems, with software and services forming a growing share of the total mix, as noted in Elekta nine?month report as of 03/13/2026. The company reported stable demand in North America and Europe, while emerging markets contributed additional system orders.

Elekta’s Unity platform, which combines MRI imaging with a linear accelerator for precision treatment, remains a strategic focus. Although the installed base is still smaller than that of conventional systems, Unity is designed to support premium pricing and margin potential over time, particularly at advanced cancer centers in the US and Western Europe, according to comments in the March 2026 earnings material from Elekta presentations as of 03/13/2026.

Service contracts and software subscriptions also play an increasingly important role. These recurring revenues can reduce cyclicality linked to capital equipment cycles and offer more predictable cash flows. For investors watching Elekta AB, the development of the service and software share in total sales is therefore an important indicator for the company’s long?term earnings quality.

Why Elekta AB matters for US investors

Even though Elekta AB is listed in Stockholm, the company generates a meaningful portion of its business in North America and competes directly with US?based med?tech groups in radiation oncology. For US investors, the stock offers exposure to global cancer treatment infrastructure and to long?term trends in oncology spending, as outlined in the company profile from Elekta in brief as of 01/2026.

Cancer incidence and access to radiotherapy equipment remain key drivers of demand worldwide. In the US, a combination of aging demographics, high treatment standards and ongoing replacement cycles for radiation systems creates a sizable market. Elekta’s focus on precision technologies and integrated software means that its competitive position in this environment is closely watched by healthcare?focused portfolios and global med?tech investors, according to sector commentary from Reuters healthcare coverage as of 02/2026.

Conclusion

Elekta AB remains a key player in radiation oncology, combining hardware, software and service revenues in a market driven by long?term cancer treatment needs. The latest nine?month 2025/26 report and guidance update underline the company’s focus on profitability and recurring revenue streams, alongside continued investment in advanced platforms such as Unity. For globally diversified and US?based investors, the stock offers focused exposure to radiotherapy infrastructure, but developments in order intake, margins and competitive dynamics will remain central variables for any future assessment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.